𝛼SK or Search

ENTITY

SinoMab Bioscience (3681 HK)

13

Analysis

Health Care • Hong Kong

SinoMab Bioscience is a clinical-stage biopharmaceutical company focused on the research, development, manufacturing, and commercialization of monoclonal antibody-based therapeutics for immunological diseases. Its flagship product, SM03 (Suciraslimab), targets rheumatoid arthritis and other autoimmune conditions. The company was founded in 2001 and is headquartered in Hong Kong.

more

Refresh

Exchange Announcement • 28 Sep 2026 16:54

Notification Letter To Non-Registered Shareholders And Reply Form

Exchange Announcement • 28 Sep 2026 16:53

Notification Letter To Registered Shareholders And Reply Form

Exchange Announcement • 28 Sep 2026 16:51

Interim Report 2026

Exchange Announcement • 18 Sep 2026 18:37

Supplemental Announcement In Relation To 2025 Annual Report

Exchange Announcement • 07 Sep 2026 17:05

Poll Results Of The Extraordinary General Meeting Held On 7 September 2026

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x